Cite
HARVARD Citation
Hegi-Johnson, F. et al. (2022). ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with 89Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol. BMJ open. 12 (11), p. . [Online].